FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025656095> ?p ?o ?g. }

• W2025656095 endingPage "505" @default.
• W2025656095 startingPage "499" @default.
• W2025656095 abstract "From June 1990 to October 1994, 111 advanced ovarian cancer patients with minimal (less than 2 cm) residual disease after platinum-based front-line chemotherapy and second-look laparotomy entered a cooperative randomized study aimed at evaluating the effectiveness and the toxicity of the addition of interferon-alpha2 to carboplatin, both intraperitoneally (ip) administered. Patients were randomized to receive either 3 courses of ip Carboplatin 400 mg/m2 Day 1 q 28 days (54 pts) (CBDCA) or ip interferon-alpha 25 x 10(6) U Day 1 + ip carboplatin 400 mg/m2 Day 2 q 28 days (57 pts) (CBDCA + IFN). Patients treated with interferon experienced more severe (WHO grade 3-4) leukopenia (28% vs 17.1%) and anemia (14% vs 4.2%). Fever (P = 0.000) and flu-like syndrome (P = 0.02) were significantly more frequent in the combination arm. No difference in gastroenteric, neurologic, or renal toxicity was observed. At a median follow-up time of 13 months (range 1-72) 71 patients showed a disease progression (31 CBDCA, 40 CBDCA + IFN) and 44 patients died (21 CBDCA, 23 CBDCA + IFN). Median progression-free survival was 11 months in the CBDCA group and 10 months in the CBDCA + IFN arm. Median survival was 22 and 29 months in CBDCA and CBDCA + IFN arm, respectively. In conclusion, intraperitoneal interferon-alpha does not seem to improve the results achievable with intraperitoneal carboplatin in this subset of patients, while the toxicity and the costs of the combination are consistently higher than with chemotherapy alone." @default.
• W2025656095 created "2016-06-24" @default.
• W2025656095 creator A5001753228 @default.
• W2025656095 creator A5015339379 @default.
• W2025656095 creator A5026141689 @default.
• W2025656095 creator A5028748860 @default.
• W2025656095 creator A5032532065 @default.
• W2025656095 creator A5034987953 @default.
• W2025656095 creator A5036472378 @default.
• W2025656095 creator A5043335329 @default.
• W2025656095 creator A5044347261 @default.
• W2025656095 creator A5052795924 @default.
• W2025656095 creator A5054546157 @default.
• W2025656095 creator A5062442517 @default.
• W2025656095 creator A5065723799 @default.
• W2025656095 creator A5067500042 @default.
• W2025656095 creator A5068312530 @default.
• W2025656095 creator A5070738538 @default.
• W2025656095 creator A5070979189 @default.
• W2025656095 creator A5074527671 @default.
• W2025656095 creator A5081516681 @default.
• W2025656095 creator A5090155553 @default.
• W2025656095 date "1997-06-01" @default.
• W2025656095 modified "2023-09-26" @default.
• W2025656095 title "Intraperitoneal Carboplatin with or without Interferon-α in Advanced Ovarian Cancer Patients with Minimal Residual Disease at Second Look: A Prospective Randomized Trial of 111 Patients" @default.
• W2025656095 cites W1869423704 @default.
• W2025656095 cites W1876291843 @default.
• W2025656095 cites W1921875169 @default.
• W2025656095 cites W1982270480 @default.
• W2025656095 cites W1996159809 @default.
• W2025656095 cites W1999551871 @default.
• W2025656095 cites W2002698549 @default.
• W2025656095 cites W2004121163 @default.
• W2025656095 cites W2034166509 @default.
• W2025656095 cites W2044611218 @default.
• W2025656095 cites W2053697068 @default.
• W2025656095 cites W2056111959 @default.
• W2025656095 cites W2062717712 @default.
• W2025656095 cites W2079436102 @default.
• W2025656095 cites W2084500050 @default.
• W2025656095 cites W2103862203 @default.
• W2025656095 cites W2111636750 @default.
• W2025656095 cites W2112430288 @default.
• W2025656095 cites W2149311269 @default.
• W2025656095 cites W2167805334 @default.
• W2025656095 cites W2241933379 @default.
• W2025656095 cites W2409767001 @default.
• W2025656095 cites W4210704032 @default.
• W2025656095 cites W4293241248 @default.
• W2025656095 doi "https://doi.org/10.1006/gyno.1997.4689" @default.
• W2025656095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9190982" @default.
• W2025656095 hasPublicationYear "1997" @default.
• W2025656095 type Work @default.
• W2025656095 sameAs 2025656095 @default.
• W2025656095 citedByCount "31" @default.
• W2025656095 countsByYear W20256560952012 @default.
• W2025656095 countsByYear W20256560952013 @default.
• W2025656095 countsByYear W20256560952015 @default.
• W2025656095 countsByYear W20256560952017 @default.
• W2025656095 countsByYear W20256560952020 @default.
• W2025656095 crossrefType "journal-article" @default.
• W2025656095 hasAuthorship W2025656095A5001753228 @default.
• W2025656095 hasAuthorship W2025656095A5015339379 @default.
• W2025656095 hasAuthorship W2025656095A5026141689 @default.
• W2025656095 hasAuthorship W2025656095A5028748860 @default.
• W2025656095 hasAuthorship W2025656095A5032532065 @default.
• W2025656095 hasAuthorship W2025656095A5034987953 @default.
• W2025656095 hasAuthorship W2025656095A5036472378 @default.
• W2025656095 hasAuthorship W2025656095A5043335329 @default.
• W2025656095 hasAuthorship W2025656095A5044347261 @default.
• W2025656095 hasAuthorship W2025656095A5052795924 @default.
• W2025656095 hasAuthorship W2025656095A5054546157 @default.
• W2025656095 hasAuthorship W2025656095A5062442517 @default.
• W2025656095 hasAuthorship W2025656095A5065723799 @default.
• W2025656095 hasAuthorship W2025656095A5067500042 @default.
• W2025656095 hasAuthorship W2025656095A5068312530 @default.
• W2025656095 hasAuthorship W2025656095A5070738538 @default.
• W2025656095 hasAuthorship W2025656095A5070979189 @default.
• W2025656095 hasAuthorship W2025656095A5074527671 @default.
• W2025656095 hasAuthorship W2025656095A5081516681 @default.
• W2025656095 hasAuthorship W2025656095A5090155553 @default.
• W2025656095 hasConcept C121608353 @default.
• W2025656095 hasConcept C126322002 @default.
• W2025656095 hasConcept C126894567 @default.
• W2025656095 hasConcept C141071460 @default.
• W2025656095 hasConcept C143998085 @default.
• W2025656095 hasConcept C2776694085 @default.
• W2025656095 hasConcept C2778239845 @default.
• W2025656095 hasConcept C2778461978 @default.
• W2025656095 hasConcept C2779823535 @default.
• W2025656095 hasConcept C2780427987 @default.
• W2025656095 hasConcept C2780873365 @default.
• W2025656095 hasConcept C2781451048 @default.
• W2025656095 hasConcept C29730261 @default.
• W2025656095 hasConcept C71924100 @default.
• W2025656095 hasConcept C90924648 @default.
• W2025656095 hasConceptScore W2025656095C121608353 @default.
• W2025656095 hasConceptScore W2025656095C126322002 @default.

• next